10 Best Debt-Free S&P 500 Stocks to Buy Now
Debt-free S&P 500 stocks are getting more attention as investors look for companies that can keep operating without depending heavily on borrowing.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 1,231,008 | $946,005,238 | +24% | 0.43% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 812,236 | $627,566,023 | +35% | 0.51% |
| 3. | GLG Partners Noam Gottesman | 315,212 | $243,545,399 | +45% | 0.44% |
| 4. | 213,700 | $165,113,168 | -20% | 0.03% | |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 192,546 | $148,768,741 | -7% | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $714.13 | 2 | $1,428.26 | 17,503 | 2026-05-01 | Filing | |
| $712.09 | 1 | $712.09 | 17,505 | 2026-05-01 | Filing | |
| $711.49 | 5 | $3,557.45 | 17,506 | 2026-05-01 | Filing | |
| $710.87 | 2 | $1,421.74 | 17,511 | 2026-05-01 | Filing | |
| $709.45 | 6 | $4,256.70 | 17,513 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,947,735 | $6,913,378,662 | 0.12% | |
| 2. | 6,654,913 | $5,141,851,981 | 0.12% | |
| 3. | 4,664,478 | $3,603,962,282 | 0.12% | |
| 4. | 4,458,238 | $3,444,613,008 | 1.89% | |
| 5. | 4,311,806 | $3,230,794,154 | 0.21% |
News See All
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical stocks to invest in according to billionaires. Canaccord cut the price target on Regeneron Pharmaceuticals, Inc.
10 Cheap NASDAQ Stocks to Buy Right Now
On April 28, Gabelli's John Belton joined CNBC's 'Closing Bell Overtime' to analyze the market environment heading into earnings season.
12 Best Medical Stocks to Invest In According to Billionaires
Talking about at what point bond yields create a meaningful risk to investors, she was of the view that if they get above the 5% range, then this “correction” or pullback will be justified.
Don’t Ignore This Market Rotation: Jim Cramer’s Views on Intel, Vertiv, TSMC, and More
In this article, we will look at the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2026 Earnings Call Transcript April 29, 2026Regeneron Pharmaceuticals, Inc. beats earnings expectations.
TD Cowen Lifts PT on Regeneron Pharmaceuticals (REGN) Ahead of Fiscal Q1 Results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best stem cell therapy stocks to buy. TD Cowen lifted the price target on Regeneron Pharmaceuticals, Inc.
Hedge Fund Resource Center